PANDAS/PANS in Children: What Parents Need to Know About Controversies and Evidence
"Understanding the complexities of PANDAS/PANS: Navigating diagnosis, treatments, and controversies with evidence-based insights for parents and caregivers."
Since first defined in 1998, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and its later, broader iteration, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), have garnered significant attention and controversy. For parents and caregivers, this can be a confusing and stressful landscape to navigate. Understanding the nuances of these conditions is essential for advocating for your child's health.
The role of streptococcal infection in children with explosive onset obsessive-compulsive disorder and new onset tics, the natural history of this entity, and the role of symptomatic and disease-modifying therapies, including antibiotics, immunotherapy, and psychoactive drugs, are all issues that have yet to be definitively addressed. This article aims to provide clarity and guidance on these complex topics, helping you make informed decisions.
While definitive proof of the autoimmune hypothesis of PANDAS is lacking, given the heightened attention to this entity and apparent rise in use of this diagnostic category, addressing questions around diagnosis, treatment, and etiology is imperative. Here, we review current working definitions of PANDAS/PANS, discuss published evidence for interventions related to this entity, and propose a clinical approach to children presenting with acute symptoms satisfying criteria for PANDAS/PANS.
Prevalence and Clinical Significance
A conservative estimate places PANDAS/PANS prevalence at 1 in 200 children in the United States, a rate comparable to pediatric cancer, diabetes, and ALS. The condition's acute onset of OCD or restrictive eating can seriously affect a child's long-term outcomes, yet research and treatment options remain scarce. Pediatric healthcare providers urgently need expert guidance to accurately diagnose and treat new-onset neuropsychiatric symptoms in children.
Consensus Guidelines and Clinical Gaps
A 2024 international consensus using the Delphi method provides the most complete and up-to-date shared indications for PANS and PANDAS diagnosis and management. Until further research establishes evidence-based treatments, clinicians must rely on current literature and clinical experience to guide care. The field continues to investigate mechanisms, biomarkers, and integrated therapeutic strategies, including evaluation of antineuronal antibody panels that may correlate with symptom changes.
From PANDAS to PANS: An Evolving Framework
PANDAS was first defined in 1998 as a pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections, characterized by sudden onset of OCD or tic disorders. In 2010, the broader category of PANS was introduced to encompass rapid-onset OCD, eating deterioration, and other behavioral and neurological symptoms not exclusively linked to strep but potentially triggered by other infectious or environmental factors. PANDAS is now considered a subtype of PANS, both marked by abrupt, severe neuropsychiatric changes in prepubertal children.
Decoding PANDAS and PANS: What Are the Key Differences?
The concept of PANDAS arose out of the hypothesis that their pathogenesis may be similar to that of Sydenham's chorea. Diagnostic criteria for PANDAS were first proposed in 1998. These criteria initially focused on the association with group A streptococcal infections, setting a specific context for diagnosis.
- PANDAS (1998): Requires a confirmed association with Group A Streptococcus (GAS) infection. Key symptoms include OCD and/or tic disorders. Primarily affects prepubescent children.
- PANS (2012): Does not require a confirmed GAS infection. Includes a broader range of neuropsychiatric symptoms beyond OCD and tics, such as anxiety, emotional lability, and behavioral regression. Can affect individuals of any age.
Emerging Research Directions
Recent literature reviews continue to summarize the evolving understanding of PANDAS and PANS phenomenology, including their relationship to OCD and tic-related illness. Research efforts are increasingly focused on identifying reliable biomarkers, clarifying immune mechanisms, and evaluating integrated therapeutic strategies. However, the evidence base remains limited, with most conclusions drawn from consensus statements rather than large-scale controlled trials.
Ongoing Controversies and Evidence Gaps
Since its inception in 1998, the PANDAS/PANS construct has generated significant controversy regarding diagnostic criteria, the role of streptococcal infection, and appropriate treatments. Literature reviews highlight fundamental disagreements among clinicians about unreported symptoms, new symptom clusters, and controversial treatment sentiments. Despite numerous investigations, evidence-based interventions remain elusive, and the field continues to debate whether these syndromes represent distinct entities or heterogeneous presentations of existing neuropsychiatric disorders.
Diagnostic Overlap and Differential Considerations
PANS and PANDAS share phenomenological features with other acute-onset neuropsychiatric conditions, including Sydenham's chorea, autoimmune encephalitis, and primary psychiatric disorders. The lack of validated biomarkers complicates differentiation, leading to diagnostic uncertainty in clinical practice. Comparative effectiveness research between immunomodulatory, psychiatric, and behavioral interventions remains sparse, limiting evidence-based treatment selection.
Recommendations for Primary Care Providers
The abrupt onset of neuropsychiatric symptoms in a previously well child warrants close and careful assessment, including a detailed history, examination, and investigations to rule out underlying etiologies. As the need to understand this group of children and standardize the clinical approach to this population is great, we provide an algorithmic approach to evaluation of a child suspected of having PANDAS/PANS.
Integrating Clinical Perspectives
Expert consensus emphasizes a multidisciplinary approach combining immunomodulatory, psychiatric, and supportive therapies tailored to individual presentations. The heterogeneous nature of PANS/PANDAS—with variable triggers, symptom clusters, and disease courses—necessitates personalized management plans. Ongoing dialogue between researchers, clinicians, and patient advocates aims to refine diagnostic frameworks and prioritize research that addresses the most pressing clinical uncertainties.
Advancing the Research Agenda
Future research priorities include large-scale prospective studies to establish incidence and natural history, identification of reliable biomarkers for diagnosis and treatment monitoring, and randomized controlled trials of immunomodulatory and behavioral interventions. Mechanistic studies exploring neuroimmune interactions and genetic susceptibility may clarify etiology and enable targeted therapies. Standardized diagnostic criteria and outcome measures are needed to accelerate multicenter collaboration and evidence generation.
Healthcare Access and Systemic Barriers
PANS features a heterogeneous constellation of acute OCD, eating restriction, cognitive, behavioral, and affective symptoms, often following a chronic relapsing course. PANDAS is characterized as a postinfectious neuroimmune syndrome with abrupt onset of OCD, tics, and neuropsychiatric symptoms temporally linked to Group A strep infection. Families face significant challenges obtaining accurate diagnosis, proper treatment, and adequate support, with limited specialized providers and inconsistent insurance coverage for immunomodulatory therapies. Leading networks emphasize the need for up-to-date research dissemination to improve clinical confidence and care quality.
Family Experience and Advocacy
The sudden, seemingly inexplicable transformation of a child's behavior and cognition places immense emotional, financial, and logistical strain on families. Caregivers often navigate a fragmented healthcare system while advocating for recognition of a condition that remains controversial in some medical circles. The relapsing-remitting course disrupts education, social development, and family functioning. Parent-led organizations have been instrumental in driving research funding, clinical awareness, and policy changes to improve outcomes for affected children.